M Pfreundschuh

Summary

Affiliation: Saarland University
Country: Germany

Publications

  1. ncbi Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF
    M Pfreundschuh
    Department of Medicine, Saarland University Medical School, Germany
    Ann Oncol 12:471-7. 2001
  2. ncbi Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    M Pfreundschuh
    Saarland University Medical School, Homburg, Germany
    Ann Oncol 19:545-52. 2008
  3. doi Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
    Michael Pfreundschuh
    Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany
    Lancet Oncol 9:105-16. 2008
  4. doi Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia
    C Zwick
    Department of Oncology, Saarland University Medical School, Homburg, Germany
    Ann Oncol 22:1872-7. 2011
  5. ncbi Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    M Pfreundschuh
    Universitatsklinikum des Saarlandes, Homburg, Germany IMISE, Leipzig, Germany Klinikum, Chemnitz, Germany AK St Georg, Hamburg, Germany Universitätsklinikum, Heidelberg, Germany Klinikum der Universität, Koln, Germany
    J Clin Oncol 26:8508. 2008
  6. doi CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    Universitatsklinikum des Saarlandes, Homburg, Germany
    Lancet Oncol 12:1013-22. 2011
  7. ncbi Aggressive craniofacial lymphoma in the pre-rituximab and rituximab era
    V Poeschel
    Department of Internal Medicine, German Non Hodgkin Lymphoma Study Group DSHNHL, Homburg, Germany Saarland University Hospital, Homburg, Germany Asklepios Klinik St Georg, Hamburg, Germany Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany Department of Radiotherapy and Radiooncology, Homburg Saar, Germany Klinikum Landshut, Landshut, Germany Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany Asklepios Hospital St Georg, Hamburg, Germany
    J Clin Oncol 29:8038. 2011
  8. ncbi The impact of high-intensity conditioning prior to allogeneic stem cell transplantation in patients with chemorefractory or relapsed T-cell lymphoma
    B Glass
    Asklepios Klinik St Georg, Hamburg, Germany University of Goettingen, Goettingen, Germany University Hospital of Giessen and Marburg, Marburg, Germany Saarland University Hospital, Homburg, Germany Asklepios Hospital St Georg, Hamburg, Germany George August University, Goettingen, Germany
    J Clin Oncol 29:8040. 2011
  9. ncbi Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSH
    N Schmitz
    Asklepios Hospital St Georg, Hamburg, Germany Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany Chemnitz Hospital, Chemnitz, Germany Klinikum der Universität zu Köln, Cologne, Germany University Hospital of Munich, Munich, Germany University Hospital Ulm, Ulm, Germany Städtisches Klinikum Karlsruhe, Karlsruhe, Germany Carl Thiem Klinikum, Cottbus, Germany University Hospital, Dresden, Germany University Hospital Greifswald, Greifswald, Germany George August University, Goettingen, Germany Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany Saarland University Hospital, Homburg, Germany Asklepios Klinik St Georg, Hamburg, Germany
    J Clin Oncol 29:8002. 2011
  10. ncbi Mature T-/NK-cell lymphomas: Prognostic factors and treatment outcome of patients treated on studies of the German High-Grade Lymphoma Study Group (DSHNHL)
    N Schmitz
    Asklepios Klinik St Georg, Hamburg, Germany University of Leipzig, Leipzig, Germany University of Goettingen, Goettingen, Germany University of Heidelberg, Heidelberg, Germany Klinikum Oldenburg, Oldenburg, Germany University of Wuerzburg, Wuerzburg, Germany Saarland University, Homburg, Germany
    J Clin Oncol 27:8564. 2009

Detail Information

Publications31

  1. ncbi Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF
    M Pfreundschuh
    Department of Medicine, Saarland University Medical School, Germany
    Ann Oncol 12:471-7. 2001
    ..The use of CSF for interval reduction rather than dose escalation is the more effective strategy for dose intensification...
  2. ncbi Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    M Pfreundschuh
    Saarland University Medical School, Homburg, Germany
    Ann Oncol 19:545-52. 2008
    ....
  3. doi Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
    Michael Pfreundschuh
    Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany
    Lancet Oncol 9:105-16. 2008
    ..This randomised trial assessed whether six or eight cycles of R-CHOP-14 can improve outcome of these patients compared with six or eight cycles of CHOP-14...
  4. doi Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia
    C Zwick
    Department of Oncology, Saarland University Medical School, Homburg, Germany
    Ann Oncol 22:1872-7. 2011
    ..To study the effects of deferring pegfilgrastim until day 4 on the reduction of chemotherapy-induced leukocytopenia...
  5. ncbi Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    M Pfreundschuh
    Universitatsklinikum des Saarlandes, Homburg, Germany IMISE, Leipzig, Germany Klinikum, Chemnitz, Germany AK St Georg, Hamburg, Germany Universitätsklinikum, Heidelberg, Germany Klinikum der Universität, Koln, Germany
    J Clin Oncol 26:8508. 2008
    ..In order to achieve high R levels early, we increased the number of R applications...
  6. doi CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    Universitatsklinikum des Saarlandes, Homburg, Germany
    Lancet Oncol 12:1013-22. 2011
    ..Extended follow-up was needed to establish long-term effects...
  7. ncbi Aggressive craniofacial lymphoma in the pre-rituximab and rituximab era
    V Poeschel
    Department of Internal Medicine, German Non Hodgkin Lymphoma Study Group DSHNHL, Homburg, Germany Saarland University Hospital, Homburg, Germany Asklepios Klinik St Georg, Hamburg, Germany Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany Department of Radiotherapy and Radiooncology, Homburg Saar, Germany Klinikum Landshut, Landshut, Germany Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany Asklepios Hospital St Georg, Hamburg, Germany
    J Clin Oncol 29:8038. 2011
    ..8038 Background: Among 4,165 patients treated in trials of the German High Grade Non-Hodgkin Lymphoma Study Group (DSHNHL), 316 pts had craniofacial involvement by their lymphoma...
  8. ncbi The impact of high-intensity conditioning prior to allogeneic stem cell transplantation in patients with chemorefractory or relapsed T-cell lymphoma
    B Glass
    Asklepios Klinik St Georg, Hamburg, Germany University of Goettingen, Goettingen, Germany University Hospital of Giessen and Marburg, Marburg, Germany Saarland University Hospital, Homburg, Germany Asklepios Hospital St Georg, Hamburg, Germany George August University, Goettingen, Germany
    J Clin Oncol 29:8040. 2011
    ..Optimal therapeutic strategies are yet to be defined. However, emerging evidence suggests a pivotal role of allogeneic stem cell transplantation in this situation...
  9. ncbi Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSH
    N Schmitz
    Asklepios Hospital St Georg, Hamburg, Germany Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany Chemnitz Hospital, Chemnitz, Germany Klinikum der Universität zu Köln, Cologne, Germany University Hospital of Munich, Munich, Germany University Hospital Ulm, Ulm, Germany Städtisches Klinikum Karlsruhe, Karlsruhe, Germany Carl Thiem Klinikum, Cottbus, Germany University Hospital, Dresden, Germany University Hospital Greifswald, Greifswald, Germany George August University, Goettingen, Germany Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany Saarland University Hospital, Homburg, Germany Asklepios Klinik St Georg, Hamburg, Germany
    J Clin Oncol 29:8002. 2011
    ..8002 Background: Studies comparing HDT with conventional first-line therapy for younger patients (pts.) with aggressive B-cell lymphoma gave conflicting results. None of these studies combined chemotherapy with Rituximab (R)...
  10. ncbi Mature T-/NK-cell lymphomas: Prognostic factors and treatment outcome of patients treated on studies of the German High-Grade Lymphoma Study Group (DSHNHL)
    N Schmitz
    Asklepios Klinik St Georg, Hamburg, Germany University of Leipzig, Leipzig, Germany University of Goettingen, Goettingen, Germany University of Heidelberg, Heidelberg, Germany Klinikum Oldenburg, Oldenburg, Germany University of Wuerzburg, Wuerzburg, Germany Saarland University, Homburg, Germany
    J Clin Oncol 27:8564. 2009
    ..We evaluated patients (pts) diagnosed according to WHO standards and treated on prospective studies of the DSHNHL. Chemotherapy regimens (CHOP-14 and CHOEP) had significantly improved outcomes of patients with aggressive B-NHL...
  11. ncbi Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20+ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL
    M Pfreundschuh
    Saarland University Hospital, Homburg, Germany Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany University Hospital, Mannheim, Germany Carl Thiem Klinikum, Cottbus, Germany Klinikum Mutterhaus, Trier, Germany University Hospital Grosshadern, Munich, Germany Department of Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany George August University, Goettingen, Germany Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany University of Freiburg, Freiburg, Germany Klinikum Oldenburg, Oldenburg, Germany Katharinenhospital, Stuttgart, Germany Department of Internal Medicine, German Non Hodgkin Lymphoma Study Group DSHNHL, Homburg, Germany Asklepios Hospital St Georg, Hamburg, Germany Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
    J Clin Oncol 29:8029. 2011
    ..8029 Background: Interval reduction from 3 (CHOP-21) to 2 wks (CHOP-14) and the addition of R to CHOP-21 (R-CHOP-21) improved outcome in elderly pts with DLBCL to a similar extent compared to CHOP-21...
  12. ncbi Model-based optimization of G-CSF treatment during chemotherapy
    M Loeffler
    Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Leipzig, Germany Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany Saarland University Hospital, Homburg, Germany
    J Clin Oncol 29:e19658. 2011
    ..We designed a predictive biomathematical modelling of granulopoiesis, illustrate our predictions for the CHOP regimen and compare the results to trial data of the German DLBCL study group...
  13. doi [Treatment of hematological malignancies with monoclonal antibodies]
    G Held
    Klinik und Poliklinik für Innere Medizin I, Universitatsklinikum des Saarlandes, Homburg Saar, 66421, Homburg, Germany
    Internist (Berl) 49:929-30, 932-4, 936-7. 2008
    ..In this review the current role of monoclonal antibodies in the treatment of different hematological neoplasms will be discussed and perspectives for their future use in leukemia and lymphomas will be shown...
  14. ncbi Tumour vaccines: a new immunotherapeutic approach in oncology
    C Renner
    Med Dept I, Saarland University Medical School, Homburg Saar, Germany
    Ann Hematol 79:651-9. 2000
    ..However, we are still at the beginning of this process and should always remember that only well-designed, prospective clinical trials can define the optimal use of tumour vaccines in oncology...
  15. ncbi Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells
    C Renner
    Med Klinik I, Universit t des Saarlandes, Homburg, Germany
    Cancer Immunol Immunother 44:70-6. 1997
    ..Our results underline the importance of the expression levels of perforin and granzymes in the effector T cells and of the proliferative state of the target cells in bi-mAb-mediated apoptosis and necrosis of tumor cells...
  16. ncbi Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet
    P Simon
    Department of Oncology and Rheumatology, Saarland University Medical School, D 66421 Homburg, Germany
    Clin Exp Rheumatol 30:45-50. 2012
    ..The aim of this study was to determine clinical factors as possible predictors for radiological damage in hands and feet of PsA patients with a 12-month follow-up...
  17. ncbi Serological identification of human tumor antigens
    U Sahin
    Medizinische Klinik I, Universitat des Saarlandes, Homburg, Germany
    Curr Opin Immunol 9:709-16. 1997
    ..The abundance of serologically defined human tumor antigens facilitates the identification of T cell dependent antigens and provides a basis for peptide and gene therapy vaccine strategies in a wide variety of human cancers...
  18. ncbi Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system
    C Renner
    Medical Department I, Saarland University, Homburg, Germany
    Cancer Immunol Immunother 50:102-8. 2001
    ....
  19. ncbi Exploitation of the B cell repertoire for the identification of human tumor antigens
    M Pfreundschuh
    Department of Medicine, Saarland University Medical School, Homburg, Germany
    Cancer Chemother Pharmacol 46:S3-7. 2000
    ..Finally, many of the antigens identified using SEREX seem to play a functional role in the pathogenesis of malignant disease...
  20. ncbi A novel system to test for specificity of B cell receptors from tissue of Wegener's granulomatosis patients
    J Voswinkel
    Saarland University Medical School, Internal Medicine I, Homburg Saar, Germany
    Clin Exp Rheumatol 26:S90-6. 2008
    ..These fab fragments have the identical antigen binding site like the B-cell receptor from which the DNA was derived...
  21. ncbi Clinical approaches to vaccination in oncology
    C Renner
    Medical Department I, Saarland University Medical School, Homburg Saar, Germany
    Ann Hematol 80:255-66. 2001
    ..The precise definition of immune parameters in these patients will then lead the way for optimised treatment procedures that might even be beneficial for a larger group of cancer patients...
  22. ncbi Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    A Wunderlich
    Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
    Ann Oncol 14:881-93. 2003
    ..To enable more extensive testing of these schemes we here characterise their practicability regarding schedule adherence, acute haematotoxicity and need for supportive treatment...
  23. ncbi Advances in molecular biology diagnostic and treatment of B-cell malignancies
    R Schmits
    Department of Internal Medicine I, University of Saarland Medical School, Homburg Saar, Germany
    Ann Oncol 16:ii105. 2005
  24. ncbi Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    V Boehme
    Department of Haematology, General Hospital St Georg, Hamburg, and Institute of Medical Informatics, Statistics and Epidemiology, University Leipzig, Germany
    Ann Oncol 18:149-57. 2007
    ....
  25. doi Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens
    L Trumper
    Hematology and Oncology, University Hospital Gottingen, Germany
    Ann Oncol 19:538-44. 2008
    ..To determine the maximum tolerated dose of a bi- and tri-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone plus etoposide (CHOEP) regimen without stem-cell support...
  26. ncbi Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma
    M Ziepert
    Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
    Ann Oncol 19:752-62. 2008
    ..Little is known on the heterogeneity of hematotoxicity in patients receiving multicycle chemotherapy...
  27. ncbi [Treatment of aggressive lymphomas]
    B Gleissner
    Medizinische Klinik I, Universitätsklinikum Saarland, Kirrberger Strasse, 66421, Homburg, Deutschland
    Internist (Berl) 48:389-95. 2007
    ..For patients > 60 years from all IPI groups, the best results have so far been achieved with six courses of R-CHOP-14 followed by two additional applications of rituximab...
  28. doi [Treatment of diffuse large B-cell lymphoma]
    B Gleissner
    Klinik fur Innere Medizin I, Universitätsklinikum Saarland, Homburg
    Dtsch Med Wochenschr 133:1785-94; quiz 1795-6. 2008
    ....
  29. ncbi A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
    F Morschhauser
    Hematology, Hopital C Huriez Centre Hospitalier Universitaire, Lille, France
    Ann Oncol 19:247-53. 2008
    ..Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses signaling through PKCbeta/PI3K/AKT pathways, induces apoptosis, reduces proliferation, and suppresses tumor-induced angiogenesis...
  30. ncbi [New diagnostic and therapeutic strategies for aggressive lymphomas]
    L Trumper
    Abteilung Hämatologie und Onkologie, Klinikum der Georg August Universität, Gottingen
    Dtsch Med Wochenschr 129:2113-7. 2004
  31. ncbi Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines
    F Hartmann
    Department of Medicine, Saarland University Medical School D-66421 Homburg, Germany
    Clin Cancer Res 7:1873-81. 2001
    ..Coadministration of cytokines might contribute to an augmented antitumor activity, and additional clinical trials are warranted to optimize this novel treatment modality...